0.9801
price down icon2.00%   -0.0199
 
loading
Precedente Chiudi:
$1.00
Aprire:
$0.98
Volume 24 ore:
11,548
Relative Volume:
0.02
Capitalizzazione di mercato:
$11.30M
Reddito:
$996.00K
Utile/perdita netta:
$-6.09M
Rapporto P/E:
-1.8492
EPS:
-0.53
Flusso di cassa netto:
$-9.76M
1 W Prestazione:
-6.67%
1M Prestazione:
+13.29%
6M Prestazione:
-38.75%
1 anno Prestazione:
-55.96%
Intervallo 1D:
Value
$0.98
$1.03
Intervallo di 1 settimana:
Value
$0.92
$1.07
Portata 52W:
Value
$0.70
$2.44

Therapeuticsmd Inc Stock (TXMD) Company Profile

Name
Nome
Therapeuticsmd Inc
Name
Telefono
561-961-1900
Name
Indirizzo
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Name
Dipendente
0
Name
Cinguettio
@TherapeuticsMD
Name
Prossima data di guadagno
2025-03-31
Name
Ultimi documenti SEC
Name
TXMD's Discussions on Twitter

Confronta TXMD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
TXMD
Therapeuticsmd Inc
0.9801 11.30M 996.00K -6.09M -9.76M -0.53
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
161.34 73.88B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.20 48.17B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.48 47.59B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.07 17.28B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
309.41 13.78B 2.76B 1.11B 898.10M 22.77

Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-08-07 Downgrade Jefferies Hold → Underperform
2020-05-19 Downgrade JP Morgan Overweight → Neutral
2019-12-02 Iniziato Guggenheim Buy
2019-10-17 Iniziato H.C. Wainwright Buy
2019-04-30 Ripresa Noble Capital Markets Outperform
2018-06-15 Iniziato JP Morgan Overweight
2017-09-08 Iniziato Morgan Stanley Equal-Weight
2017-07-11 Aggiornamento Oppenheimer Perform → Outperform
2017-05-09 Downgrade Oppenheimer Outperform → Perform
2016-11-22 Ripresa Jefferies Buy
2016-11-22 Iniziato Oppenheimer Outperform
2016-11-07 Ripresa Guggenheim Buy
2016-04-04 Iniziato Goldman Buy
2015-12-08 Reiterato Jefferies Buy
2015-12-08 Reiterato Stifel Buy
2015-09-21 Reiterato Jefferies Buy
2015-06-09 Iniziato Guggenheim Buy
2014-07-08 Iniziato FBR Capital Outperform
2014-04-17 Reiterato Noble Financial Buy
2014-01-28 Reiterato Noble Financial Buy
Mostra tutto

Therapeuticsmd Inc Borsa (TXMD) Ultime notizie

pulisher
Apr 02, 2025

TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 02, 2025
pulisher
Apr 02, 2025

TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 31, 2025
pulisher
Mar 29, 2025

TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023) - Yahoo Finance

Mar 29, 2025
pulisher
Mar 29, 2025

TherapeuticsMD Reports Improved Financial Performance - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch

Mar 28, 2025
pulisher
Mar 27, 2025

DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 -- TXMD - ACCESS Newswire

Mar 27, 2025
pulisher
Mar 27, 2025

TherapeuticsMD Inc. (TXMD) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

TherapeuticsMD Reports Reduced Losses and Revenue Growth - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

TherapeuticsMD Earnings: Net Loss Slashed by $5.4M as Royalty Strategy Pays Off - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

TherapeuticsMD Announces Full Year 2024 Financial Results - Business Wire

Mar 26, 2025
pulisher
Mar 18, 2025

TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Mar 18, 2025
pulisher
Mar 16, 2025

Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Business Wire

Mar 16, 2025
pulisher
Mar 13, 2025

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 13, 2025
pulisher
Mar 12, 2025

TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch

Mar 12, 2025
pulisher
Mar 07, 2025

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Mar 07, 2025
pulisher
Feb 28, 2025

TherapeuticsMD, Inc. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Investor Network: TherapeuticsMD, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Feb 26, 2025
pulisher
Feb 25, 2025

Cosette paying $430M for Mayne's women’s health, dermatology franchise - BioWorld MedTech

Feb 25, 2025
pulisher
Feb 21, 2025

How does TXMD’s price to cash per share ratio compare in the market? - US Post News

Feb 21, 2025
pulisher
Jan 14, 2025

StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World

Jan 14, 2025
pulisher
Jan 10, 2025

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch

Jan 10, 2025

Therapeuticsmd Inc Azioni (TXMD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Therapeuticsmd Inc Azioni (TXMD) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Naughton Gail K
Director
Feb 18 '25
Option Exercise
0.00
8,500
0
8,500
Thompson Tommy G
Director
Feb 18 '25
Option Exercise
0.00
8,500
0
14,454
Walker Marlan D
Chief Executive Officer
Feb 18 '25
Option Exercise
0.00
8,281
0
70,846
Collins Cooper C.
Director
Aug 22 '24
Buy
1.73
4,094
7,099
52,016
Collins Cooper C.
Director
Aug 21 '24
Buy
1.70
1,200
2,039
47,922
$9.95
price down icon 7.85%
$32.55
price up icon 0.31%
$95.31
price down icon 2.00%
$8.525
price down icon 0.93%
$105.98
price down icon 1.57%
$300.42
price down icon 4.61%
Capitalizzazione:     |  Volume (24 ore):